#57. Do You Turst your AI?

These sources present a framework for transitioning from vague notions of "trusting" artificial intelligence in drug discovery toward a more rigorous system of calibrated reliance. Both documents emphasize that AI reliability must be evaluated within a specific context of use, requiring a transition from retrospective performance claims to prospective, leakage-resistant validation. To manage the high risks of pharmaceutical research, the authors propose a six-layer trust stack that addresses data integrity, biological validity, and institutional governance. A central technical recommendation is the implementation of a Trust Ledger, a machine-readable record that logs every prediction's provenance, uncertainty, and experimental feedback. The papers also advocate a human-governed, AI-executed model in which autonomous agents perform continuous auditing while human experts maintain final accountability. Ultimately, the text argues that the future of therapeutics depends on treating AI outputs as auditable hypotheses rather than definitive discoveries. Produced by Dr. Jake Chen.